Business Standard

Aurobindo Pharma gains 5% post December quarter results

The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.

Aurobindo Pharma wrests second position among drug firms from Lupin
Premium

Aurobindo Pharma

SI Reporter Mumbai
Shares of Aurobindo Pharma gained 5 per cent to Rs 538 on the BSE on Friday after the company’s operational revenues witnessed a strong growth of 11.9 per cent year-on-year (YoY) at Rs 5,895 crore in December quarter (Q3FY20). US revenue for Q3FY20 witnessed a growth of 22 per cent YoY to Rs 2,969 crore, accounting for 50.4 per cent of consolidated revenue.

The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.

The company’s consolidated

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in